Akadeum Life Sciences plans to expand commercialization of proprietary biological separation platform

Akadeum Life Sciences, Inc., today announced the closing of its oversubscribed $17.5 million Series B financing round, including an initial investment by Beringea U.S. Proceeds from the financing will be used to advance global commercialization for Akadeum’s proprietary microbubble-based separation platform, with applications spanning life science research, including cell therapy and diagnostics. The company will also advance efforts to develop new business-to-business partnerships and expand R&D and new product development.

Using its proprietary microbubble-based technology to easily float target cells, nucleic acids and other biological targets to the top of a sample, Akadeum’s next-generation platform allows for virtually any biological entity to be captured. Akadeum’s technology solves long-standing problems in separation processes, including volume and throughput restrictions, exceeding the performance, system cost, and scalability of current technologies.

“This funding brings new momentum to our effort to deploy our technology platform to empower new scientific discoveries, improve diagnostic sensitivity, and increase access to novel cell therapies,” said Brandon H. McNaughton, PhD, Akadeum’s President and CEO. “The success of this financing is another indication of the growing interest in the applications of the Akadeum platform technology,” added McNaughton.

“We’re excited to partner with Akadeum and about the possibilities Akadeum’s cell separation technology represents across life science applications” said John Bonhard, vice president at Beringea. “The accelerated pace of separations which Akadeum clients can realize from this faster, more cost-effective process could lead to a faster path to cures and treatments around the world.”